Literature DB >> 32953130

SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2.

Jingfang Mu1,2, Yaohui Fang1, Qi Yang1, Ting Shu1,2, An Wang1,3, Muhan Huang1,2, Liang Jin4, Fei Deng1,2, Yang Qiu1,2, Xi Zhou1,2,3,4.   

Abstract

Entities:  

Keywords:  Immunology; Molecular biology

Year:  2020        PMID: 32953130      PMCID: PMC7490572          DOI: 10.1038/s41421-020-00208-3

Source DB:  PubMed          Journal:  Cell Discov        ISSN: 2056-5968            Impact factor:   10.849


× No keyword cloud information.
  4 in total

Review 1.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

2.  The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination.

Authors:  Yong Hu; Wei Li; Ting Gao; Yan Cui; Yanwen Jin; Ping Li; Qingjun Ma; Xuan Liu; Cheng Cao
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 3.  The coronavirus nucleocapsid is a multifunctional protein.

Authors:  Ruth McBride; Marjorie van Zyl; Burtram C Fielding
Journal:  Viruses       Date:  2014-08-07       Impact factor: 5.048

4.  SARS-CoV-2-encoded nucleocapsid protein acts as a viral suppressor of RNA interference in cells.

Authors:  Jingfang Mu; Jiuyue Xu; Leike Zhang; Ting Shu; Di Wu; Muhan Huang; Yujie Ren; Xufang Li; Qing Geng; Yi Xu; Yang Qiu; Xi Zhou
Journal:  Sci China Life Sci       Date:  2020-04-10       Impact factor: 6.038

  4 in total
  49 in total

Review 1.  Virus Caused Imbalance of Type I IFN Responses and Inflammation in COVID-19.

Authors:  Jintao Zhang; Chunyuan Zhao; Wei Zhao
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

2.  Evolution and Epidemiology of SARS-CoV-2 Virus.

Authors:  Yu-Nong Gong; Kuo-Ming Lee; Shin-Ru Shih
Journal:  Methods Mol Biol       Date:  2022

Review 3.  Characterization of SARS-CoV-2 Evasion: Interferon Pathway and Therapeutic Options.

Authors:  Mariem Znaidia; Caroline Demeret; Sylvie van der Werf; Anastassia V Komarova
Journal:  Viruses       Date:  2022-06-08       Impact factor: 5.818

Review 4.  Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19.

Authors:  Shea A Lowery; Alan Sariol; Stanley Perlman
Journal:  Cell Host Microbe       Date:  2021-05-17       Impact factor: 21.023

5.  SARS-CoV-2 Induces Lymphocytopenia by Promoting Inflammation and Decimates Secondary Lymphoid Organs.

Authors:  Qun Xiang; Zeqing Feng; Bo Diao; Chao Tu; Qinghua Qiao; Han Yang; Yi Zhang; Gang Wang; Huiming Wang; Chenhui Wang; Liang Liu; Changsong Wang; Longding Liu; Rong Chen; Yuzhang Wu; Yongwen Chen
Journal:  Front Immunol       Date:  2021-04-28       Impact factor: 7.561

Review 6.  The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis.

Authors:  Nicholas A Wong; Milton H Saier
Journal:  Int J Mol Sci       Date:  2021-01-28       Impact factor: 6.208

Review 7.  ADP-ribosylation in evasion, promotion and exacerbation of immune responses.

Authors:  Maria Manuela Rosado; Claudio Pioli
Journal:  Immunology       Date:  2021-04-12       Impact factor: 7.215

Review 8.  Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm.

Authors:  Xiang Peng; Yani Wang; Xiangwen Xi; Ying Jia; Jiangtian Tian; Bo Yu; Jinwei Tian
Journal:  Cardiovasc Drugs Ther       Date:  2021-01-06       Impact factor: 3.727

9.  Endothelial Senescence and Chronic Fatigue Syndrome, a COVID-19 Based Hypothesis.

Authors:  Adonis Sfera; Carolina Osorio; Carlos M Zapata Martín Del Campo; Shaniah Pereida; Steve Maurer; Jose Campo Maldonado; Zisis Kozlakidis
Journal:  Front Cell Neurosci       Date:  2021-06-25       Impact factor: 5.505

Review 10.  The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation.

Authors:  Zhihua Bai; Ying Cao; Wenjun Liu; Jing Li
Journal:  Viruses       Date:  2021-06-10       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.